TradingView
MarketMoversReport
Aug 31, 2022 6:58 PM

FDA Grants Orphan Drug Designation for BioCryst’s ALK2 Inhibitor Long

NASDAQ:BCRX1D
BioCryst Pharmaceuticals, Inc.NASDAQ

Description

⋅
BCRX: BioCryst Pharmaceuticals, Inc.
2022-08-31 07:00:00 FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva
Beyond Technical Analysis
More